Entecavir Versus Lamivudine for Preventing the Risk of Hepatitis B Reactivation in NHL
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01914744
Recruitment Status : Unknown
Verified July 2013 by Ye Guo, Fudan University. Recruitment status was: Recruiting
The aim of this study is to prove the superiority of entecavir over lamivudine for preventing the risk of hepatitis B virus reactivation in patients with non-Hodgkin lymphoma on CHOP/R-CHOP.
Condition or disease
Non-Hodgkin LymphomaHepatitis B Reactivation
Drug: EntecavirDrug: Lamivudine
In china, previous studies showed patients with non-Hodgkin lymphoma (NHL) are likely to have hepatitis B virus (HBV) infection. The risk of HBV reactivation is high when patients were treated with CHOP, especially in combination with rituximab. The aim of this study is to compare entecavir with lamivudine, 2 commonly used anti-virus agents, for preventing the risk of HBV reactivation in patients with NHL on CHOP/R-CHOP.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years to 80 Years (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Previously untreated NHL suitable for CHOP/R-CHOP treatment
Age range 18-80 years old
HBsAg positive with high level of HBV DNA
Eastern Cooperative Oncology Group performance status 0-2
Life expectancy of more than 3 months
Adequate organ function
Primary or secondary central nervous system involvement
With hepatitis C virus infection
Previous serious cardiac disease
History of other malignancies except cured basal cell carcinoma of skin and carcinoma in-situ of uterine cervix
Pregnant or lactating women
Serious uncontrolled diseases and intercurrent infection
Neoplasms by Histologic Type
Immune System Diseases
Digestive System Diseases
Hepatitis, Viral, Human